| 申高飞 李进晶 汪鑫 耿蕾 王新.肿瘤的分子分型在当代结直肠癌中的应用[J].,2015,15(10):1994-1997 |
| 肿瘤的分子分型在当代结直肠癌中的应用 |
| Applications of Molecular Classification in Colorectal Cancer |
| |
| DOI： |
| 中文关键词: 肿瘤 分子分型 结直肠癌 |
| 英文关键词: Carcinoma Molecular classification Colorectal cancer |
| 基金项目:国家自然科学基金面上项目（81272650；81472701） |
|
| 摘要点击次数: 683 |
| 全文下载次数: 1979 |
| 中文摘要: |
| 以分子检测为基础的肿瘤分子分型及个体化治疗方案使当代的结直肠癌治疗逐步走向“同病异治”模式，结直肠癌同病异
治两个最常见的应用，一是RAS 基因突变与分子靶向药物的应用，二是微卫星不稳定（MSI）状态与林奇综合征的诊断和治疗。其
中RAS 基因野生型患者使用西妥昔单抗联合化疗方案获益显著，而林奇综合征的患者与微卫星稳定患者相比，显示了更好的预
后，且其不能从化疗药物氟尿嘧啶中获益。然而，为了让更多的结肠癌患者获益，我们还需要继续探寻对结肠癌更有效更全面的
分子分型标准。 |
| 英文摘要: |
| Based on the modern molecular detection, molecular classification of tumors and individualized treatment plan
successfully makes the patient with the same disease treated with various methods. And the most widely used are the RAS gene mutations
with the molecular targeted drugs applied and MSI status with lynch syndrome diagnoed and treatment. However, the benefit of
cetuximab was limited to patients with RAS wild-type tumors, and patients of lynch syndrome have a better prognosis but no benefits
fromfluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable tumors. Then we are led to explore
more effectively and comprehensive molecular classification standards to benefit more patients with colorectal cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
